{"filing":{"accession_number":"0001171843-26-006050","cik":"0001801198","ticker":"LEGN","company_name":"Legend Biotech Corp","form":"6-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"f6k_091526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1801198/000117184326006050/f6k_091526.htm"},"events":[{"id":33478,"run_id":30783,"accession_number":"0001171843-26-006050","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Legend Biotech's Board of Directors appointed Ingrid Zhang as Chief Executive Officer effective September 15, 2026, following a comprehensive Board-led search process. This is a material executive appointment of a named officer to a principal leadership role. Alan Bash, who served as Interim CEO since July 2026, resumes his role as President, CARVYKTI. The appointment of a new CEO from an external candidate with significant industry experience (former Chief Commercial Officer at Novartis) is a material governance event affecting the registrant's leadership structure.","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-09-15","form":"6-K","submitted_at":null,"items":[{"id":36932,"accession_number":"0001171843-26-006050","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"Legend Biotech's Board of Directors appointed Ingrid Zhang as Chief Executive Officer effective September 15, 2026, following a comprehensive Board-led search process. This is a material executive appointment of a named officer to a principal leadership role. Alan Bash, who served as Interim CEO since July 2026, resumes his role as President, CARVYKTI. The appointment of a new CEO from an external candidate with significant industry experience (former Chief Commercial Officer at Novartis) is a material governance event affecting the registrant's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:02:08.745131+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36932,"accession_number":"0001171843-26-006050","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"Legend Biotech's Board of Directors appointed Ingrid Zhang as Chief Executive Officer effective September 15, 2026, following a comprehensive Board-led search process. This is a material executive appointment of a named officer to a principal leadership role. Alan Bash, who served as Interim CEO since July 2026, resumes his role as President, CARVYKTI. The appointment of a new CEO from an external candidate with significant industry experience (former Chief Commercial Officer at Novartis) is a material governance event affecting the registrant's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:02:08.745131+00:00","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-09-15"}]}